Test tumor-like cell clusters to predict progesterone response
Part of Cancer, Women’s health & pregnancy clinical trials.
This study looks at small lab samples taken from early endometrial cancer to see how sensitive the tumor is to progesterone treatment. It may help doctors choose the safest treatment that preserves fertility and the uterus for the right patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your diagnosis must be early endometrial changes: either atypical endometrial hyperplasia or well-differentiated endometrial cancer grade 1 (EEC G1), with no spread into the uterine muscle
- Your scans (MRI/CT/ultrasound) must not show suspicious spread outside the uterus
- You must want to keep your uterus and future pregnancy options
- You need to be able and willing to follow the study treatment and come to follow-up visits
- You must not have serious liver problems, liver tumors, or kidney dysfunction
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the weight-loss drug orlistat to standard hormone therapy can help shrink early-stage endometrial cancer or precancerous changes, so you can avoid having your uterus removed and still try for a baby later.
This study looks at how ultrasound and tissue samples (histology) can better guide fertility-sparing treatment for early uterine cancer or precancer. It aims to improve how doctors decide on surgery or hormone therapy to preserve fertility.
This trial tests whether adding GnRH medicine and letrozole to standard progestin treatment can better control early, low-risk endometrial cancer or atypical hyperplasia in people who are not obese. It may help some patients avoid progression while keeping the uterus, especially for those wanting future fertility.
This study looks at whether a hormone-releasing IUD (LNG-IUS) can treat early-stage endometrial cancer or very early abnormal cell growth while helping you keep the option for future pregnancy. It aims to see how well the treatment works and how it affects fertility-related outcomes.
This study looks for “methylated DNA markers” (special DNA patterns) to help detect endometrial, ovarian, and cervical cancers, and to support doctors around planned procedures. It may help find cancer earlier or better sort out who needs closer treatment.
This study tests a way to treat early-stage endometrial cancer without removing the uterus, so you can still have a chance to carry a pregnancy. It’s for women under 45 with a grade 2 tumor that hasn’t grown into the womb muscle.
Hear when a new Atypical Endometrial Hyperplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.